CSL Statutory Accounts for FY2025

• Revenue up 5% to US$15.558 billion
• NPAT up 14% to US$3.002 billion
• NPATA up 11% to US$3.219 billion
• Proposed demerger of CSL Seqirus
• Strategic initiatives to improve clinical and commercial execution

CSL Limited has reported strong financial results for the full year ended 30 June 2025, with revenue up 5% to US$15.558 billion, NPAT up 14% to US$3.002 billion, and NPATA up 11% to US$3.219 billion. The company's performance was driven by continued growth across its core businesses. To further enhance its competitiveness and growth, CSL has embarked on a series of strategic initiatives to reduce cost and complexity, including a proposal to demerge its CSL Seqirus business as a separate ASX-listed entity. This will allow both CSL and Seqirus to pursue their own growth strategies and focus on their core capabilities.The company's Board of Directors has also been refreshed with the addition of two new directors, Dr Brian Daniels and Cameron Price, who bring valuable skills and expertise to support CSL's future direction.Overall, CSL remains confident in its outlook and ability to deliver enduring patient impact in areas of high unmet medical need, which will underpin sustainable, profitable growth for shareholders.

CSL expects to maintain its strong financial performance, with revenue, NPAT, and NPATA all forecast to continue growing in the 2025/26 financial year.

CSL is focused on executing its strategic initiatives to improve clinical and commercial execution, while also pursuing the proposed demerger of its Seqirus business. These actions are expected to enhance the company's competitiveness and drive further growth in the years ahead.